Search

Your search keyword '"Medical test kit industry -- Laws, regulations and rules"' showing total 1,129 results

Search Constraints

Start Over You searched for: Descriptor "Medical test kit industry -- Laws, regulations and rules" Remove constraint Descriptor: "Medical test kit industry -- Laws, regulations and rules"
1,129 results on '"Medical test kit industry -- Laws, regulations and rules"'

Search Results

201. Commerzbank AG - 0RLW - Pre Stabilisation - Fresenius EUR 3 Tranche

202. New Rules Adopted For Medical Devices

203. New Jersey Rejects Bogus Exclusion of FDA Device Clearance Evidence

204. Regulation For Rigorous Clinical Investigation Of Medical Devices: The Missing Link Of The Atma-nirbhar Drive In Healthcare

205. This Week At The Ninth: Biomaterials And Unclean Hands

206. HRDC takes Fresenius Medical Care to ACB over corrupt deal at Queens hospital

207. Fresenius Medical Care Capital Arena, LLC Files SEC Form D, Notice of Exempt Offering of Securities: (Dec. 14, 2021)

208. The case for quality: complying with FDA regulations does not guarantee a quality system or product

209. Medical device innovation in America: tensions between food and drug law and patent law.

210. Hiding across the Atlantic: U.S. drug and device companies are increasingly trying to block discovery by hiding behind European privacy laws. If you bring a suit against a company with foreign affiliates, you should be aware of the challenge and prepared to overcome it.

211. The proposed rule on transparency reports: Shedding Light on the Sunshine Act (part II): the impact of the proposed regulations on manufacturers, providers, and suppliers

212. Medical device trials: understanding the United States' regulatory pathways and clinical operations

213. Common issues not enough to allow class certification in a medical monitoring case

214. E Med Future, Inc. Files SEC Form 1-A, Offering Statement [Regulation A]: (Nov. 5, 2021)

215. What every pharmaceutical and medical device company should know: False Claims Act cases based on off-label promotion promise to increase with the healthcare act and the bad ad program.

216. Beware of costly consequences: noncompliance with the US Foreign Corrupt Practices Act carries heavy penalties

217. Hidden truth: the perils and protection of off-label drug and medical device promotion.

218. Tighter enrollment standards for medical equipment suppliers: details about the new regulations and their implications

219. Handling litigation when criminal activity is involved.

220. Temperature rising: court finds coverage for mercury contamination from thermometer factory.

221. Review of the CDRH/CBER Bayesian guidance

222. Extraterritorial reach of the FCPA: recommendations for U.S. medical device companies with activities in Europe.

223. The meaning of the parallel requirements exception under Lohr and Riegel.

224. Coping with change: medical device regulatory experts provide perspectives of what might take place under the new FDA leadership

225. Combination products--engineering the future of healthcare

226. New Mass. rules may require upgrade to existing systems

227. Biotech's hidden stepsister

228. Federal regulatory pre-emption of state tort claims against the manufacturers of medical devices and pharmaceutical drugs.

229. A new phase of pharmaceutical regulation.

230. Avoiding potential or ordered recalls.

231. Precluding disclosure under FOIA requests.

232. How to develop an effective design control program: a life-cycle multi-phase approach

233. Manufacturer liability for off-label uses of medical devices.

234. Strengthening Of The Golden Power Of The Italian Government In Areas Of Strategic Importance (Articles 15, 16 And 17 Of Law Decree 23/2020 Converted By Law 40/2020)

235. Becton Dickinson (carefusion) Pleurx Catheters And Related Items

236. Investor Alert: Kaplan Fox Continues To Investigate Boston Scientific Corporation (BSX)

237. Investor Alert: Kaplan Fox Investigates Boston Scientific Corporation (BSX)

238. Fresenius Medical Care Central Lawrenceville, LLC Files SEC Form D, Notice of Exempt Offering of Securities: (Oct. 1, 2021)

239. Fresenius Medical Care Green Bay, LLC Files SEC Form D, Notice of Exempt Offering of Securities: (Oct. 1, 2021)

240. The self-critical analysis privilege in the context of drug & medical device litigation.

241. Globalisation, harmonisation and the regulation of therapeutic products: the Australia New Zealand Therapeutic Products Authority project in global context.

242. Defending warnings - based claims against manufacturers.

243. The new FDA preemption preamble.

244. Medical product information incentives and the transparency paradox.

245. Your business in court - 2006.

246. Making room to innovate: many medical companies feel restricted from being truly innovative by government regulations. But advanced CAD software is freeing up time in development cycles to give engineers the freedom to be creative

247. In-House Counsel: Michelle Miller

248. Points to consider in the application of quality system requirements to medical devices intended for use in clinical testing

249. The Food and Drug Administration's evolving regulation of press releases: limits and challenges.

250. Humanitarian use devices: the regulatory framework for orphan devices: ensuring medical devices are used for appropriate purposes and by appropriate clinicians

Catalog

Books, media, physical & digital resources